Clinical Trial Update: A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Daiichi Sankyo's U3-1402 in advanced or metastatic colorectal cancer has been terminated in a Phase 2 study, with results posted in May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• U3-1402 (patritumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-05-18